HealthTech Connex’s subsidiary NeuroCatch has secured a medical device licence from Health Canada for the latest version of its NeuroCatch Platform brain function assessment system.

The earlier NeuroCatch generation had already secured approval from the Canadian regulatory authority in 2019 and is presently being used in several clinical studies across North America.

The brain scanner enables quick and objective analysis of cognitive brain function at the point of care and in a matter of minutes.

It is used across Canada and the US to analyse concussions and other neurological issues.

In the latest generation, the sensitivity that NeuroCatch offers is ten to 15 times more advanced, which in turn aids in identifying subtle but important alterations in the functions of the brain while monitoring neurological conditions, such as brain injuries and concussions.

Furthermore, the NeuroCatch Platform can be used for several health conditions, including brain injuries, neurological diseases, mental health issues and brain optimisation.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The latest approval from Health Canada comes after the device received Food and Drug Administration (FDA) clearance in the US.

HealthTech Connex president and chief scientific officer Dr Ryan D’Arcy said: “We’re incredibly proud that Health Canada has quickly provided our latest medical device approval for the next generation of NeuroCatch.

“As a leading R&D company in neurotechnology, we are committed to the highest possible quality through pioneering scientific breakthroughs. The capabilities embedded within this next-generation NeuroCatch represents a major leap forward, offering healthcare practitioners and researchers even greater evidence-based evaluation capabilities to quickly and accurately provide an objective measurement of cognitive function, which is delivered in minutes at the point of care.”

Claimed to be the first completely accessible and portable cognitive brain scanner, NeuroCatch features brainwave (electro-encephalography or EEG) sensors set in a mesh cap that interfaces with a hardware/ software platform to provide medical-grade results.

The NeuroCatch Platform can be used by healthcare professionals and researchers at any point of care, including in healthcare settings such as clinics, labs, hospitals and sporting venues.

The latest generation of NeuroCatch serves as a cloud-based platform offering real-time access to radar plots, showing the largest published normative reference value datasets.

It uses a trademarked EPiO Adapter to offer ten to 15 times improved temporal precision and sensitivity.

Given that the latest version offers quick, objective and physiological cognitive reporting, it enables sensitive digital cognitive function measures.